Do analysts rate TMDIF or VVOS?

Vivos Therapeutics has a consensus target price of $2.80, suggesting a potential upside of 1,003.23%. Given Vivos Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Vivos Therapeutics is more favorable than Titan Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Titan Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Vivos Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is IRIX or VVOS more profitable?

IRIDEX has a net margin of -6.88% compared to Vivos Therapeutics' net margin of -122.00%. IRIDEX's return on equity of 0.00% beat Vivos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets IRIDEX -6.88% N/A -12.55% Vivos Therapeutics -122.00% -2,325.64% -102.01%

Does the media refer more to ADGM or VVOS?

In the previous week, Vivos Therapeutics had 2 more articles in the media than Adagio Medical. MarketBeat recorded 5 mentions for Vivos Therapeutics and 3 mentions for Adagio Medical. Vivos Therapeutics' average media sentiment score of 1.17 beat Adagio Medical's score of 0.62 indicating that Vivos Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adagio Medical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vivos Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor HSCS or VVOS?

In the previous week, Vivos Therapeutics had 2 more articles in the media than HeartSciences. MarketBeat recorded 5 mentions for Vivos Therapeutics and 3 mentions for HeartSciences. Vivos Therapeutics' average media sentiment score of 1.17 beat HeartSciences' score of 0.44 indicating that Vivos Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HeartSciences 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Vivos Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend VVOS or MBAI?

Vivos Therapeutics currently has a consensus price target of $2.80, suggesting a potential upside of 1,003.23%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Vivos Therapeutics is more favorable than Check-Cap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivos Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to VVOS or MBAI?

In the previous week, Vivos Therapeutics had 2 more articles in the media than Check-Cap. MarketBeat recorded 5 mentions for Vivos Therapeutics and 3 mentions for Check-Cap. Vivos Therapeutics' average media sentiment score of 1.17 beat Check-Cap's score of 0.72 indicating that Vivos Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vivos Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Check-Cap 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vivos Therapeutics (VVOS) Competitors

$0.25 -0.01 (-4.30%)

As of 04:00 PM Eastern

Compare

VVOS vs. TMDIF, IRIX, ADGM, HSCS, and MBAI

Should you buy Vivos Therapeutics stock or one of its competitors? Vivos Therapeutics's main competitors and comparable companies include Titan Medical (TMDIF), IRIDEX (IRIX), Adagio Medical (ADGM), HeartSciences (HSCS), and Check-Cap (MBAI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Vivos Therapeutics compare to Titan Medical?

Titan Medical (NASDAQ:TMDIF) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Titan Medical has higher revenue and earnings than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Titan Medical	$17.63M	0.75	$6.95M	$0.05	2.31
Vivos Therapeutics	$17.44M	0.20	-$21.17M	-$1.90	N/A

In the previous week, Vivos Therapeutics had 5 more articles in the media than Titan Medical. MarketBeat recorded 5 mentions for Vivos Therapeutics and 0 mentions for Titan Medical. Vivos Therapeutics' average media sentiment score of 1.17 beat Titan Medical's score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Titan Medical	Neutral
Vivos Therapeutics	Positive

0.0% of Titan Medical shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 0.0% of Titan Medical shares are held by company insiders. Comparatively, 2.1% of Vivos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Titan Medical has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.22, indicating that its stock price is 522% more volatile than the broader market.

Vivos Therapeutics has a consensus target price of $2.80, suggesting a potential upside of 1,003.23%. Given Vivos Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Vivos Therapeutics is more favorable than Titan Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Titan Medical has a net margin of 0.00% compared to Vivos Therapeutics' net margin of -122.00%. Titan Medical's return on equity of -82.31% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Titan Medical	N/A	-82.31%	-51.47%
Vivos Therapeutics	-122.00%	-2,325.64%	-102.01%

Summary

Titan Medical and Vivos Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Vivos Therapeutics compare to IRIDEX?

IRIDEX (NASDAQ:IRIX) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

IRIDEX has a net margin of -6.88% compared to Vivos Therapeutics' net margin of -122.00%. IRIDEX's return on equity of 0.00% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IRIDEX	-6.88%	N/A	-12.55%
Vivos Therapeutics	-122.00%	-2,325.64%	-102.01%

20.1% of IRIDEX shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 8.6% of IRIDEX shares are owned by company insiders. Comparatively, 2.1% of Vivos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

IRIDEX has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.22, indicating that its stock price is 522% more volatile than the broader market.

In the previous week, Vivos Therapeutics had 4 more articles in the media than IRIDEX. MarketBeat recorded 5 mentions for Vivos Therapeutics and 1 mentions for IRIDEX. Vivos Therapeutics' average media sentiment score of 1.17 beat IRIDEX's score of 0.44 indicating that Vivos Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
IRIDEX	Neutral
Vivos Therapeutics	Positive

IRIDEX currently has a consensus price target of $3.00, suggesting a potential upside of 324.09%. Vivos Therapeutics has a consensus price target of $2.80, suggesting a potential upside of 1,003.23%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Vivos Therapeutics is more favorable than IRIDEX.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IRIDEX	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

IRIDEX has higher revenue and earnings than Vivos Therapeutics. IRIDEX is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IRIDEX	$52.67M	0.24	-$4.44M	-$0.20	N/A
Vivos Therapeutics	$17.44M	0.20	-$21.17M	-$1.90	N/A

Summary

IRIDEX and Vivos Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Vivos Therapeutics compare to Adagio Medical?

Adagio Medical (NASDAQ:ADGM) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Adagio Medical has a net margin of 0.00% compared to Vivos Therapeutics' net margin of -122.00%. Adagio Medical's return on equity of -661.85% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagio Medical	N/A	-661.85%	-73.35%
Vivos Therapeutics	-122.00%	-2,325.64%	-102.01%

Adagio Medical currently has a consensus target price of $3.50, suggesting a potential upside of 570.50%. Vivos Therapeutics has a consensus target price of $2.80, suggesting a potential upside of 1,003.23%. Given Vivos Therapeutics' higher possible upside, analysts clearly believe Vivos Therapeutics is more favorable than Adagio Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagio Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

48.1% of Adagio Medical shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 7.8% of Adagio Medical shares are owned by insiders. Comparatively, 2.1% of Vivos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Adagio Medical has a beta of -0.15, indicating that its stock price is 115% less volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.22, indicating that its stock price is 522% more volatile than the broader market.

In the previous week, Vivos Therapeutics had 2 more articles in the media than Adagio Medical. MarketBeat recorded 5 mentions for Vivos Therapeutics and 3 mentions for Adagio Medical. Vivos Therapeutics' average media sentiment score of 1.17 beat Adagio Medical's score of 0.62 indicating that Vivos Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adagio Medical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vivos Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vivos Therapeutics has higher revenue and earnings than Adagio Medical. Adagio Medical is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagio Medical	$600K	19.32	-$25.08M	-$1.48	N/A
Vivos Therapeutics	$17.44M	0.20	-$21.17M	-$1.90	N/A

Summary

Adagio Medical and Vivos Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Vivos Therapeutics compare to HeartSciences?

HeartSciences (NASDAQ:HSCS) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

In the previous week, Vivos Therapeutics had 2 more articles in the media than HeartSciences. MarketBeat recorded 5 mentions for Vivos Therapeutics and 3 mentions for HeartSciences. Vivos Therapeutics' average media sentiment score of 1.17 beat HeartSciences' score of 0.44 indicating that Vivos Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HeartSciences	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vivos Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

HeartSciences has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.22, suggesting that its stock price is 522% more volatile than the broader market.

HeartSciences presently has a consensus price target of $8.00, suggesting a potential upside of 167.56%. Vivos Therapeutics has a consensus price target of $2.80, suggesting a potential upside of 1,003.23%. Given Vivos Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Vivos Therapeutics is more favorable than HeartSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

HeartSciences has a net margin of 0.00% compared to Vivos Therapeutics' net margin of -122.00%. HeartSciences' return on equity of -358.60% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartSciences	N/A	-358.60%	-144.82%
Vivos Therapeutics	-122.00%	-2,325.64%	-102.01%

HeartSciences has higher earnings, but lower revenue than Vivos Therapeutics. HeartSciences is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartSciences	N/A	N/A	-$9.14M	-$3.94	N/A
Vivos Therapeutics	$17.44M	0.20	-$21.17M	-$1.90	N/A

17.2% of HeartSciences shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 4.9% of HeartSciences shares are held by insiders. Comparatively, 2.1% of Vivos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Vivos Therapeutics beats HeartSciences on 11 of the 15 factors compared between the two stocks.

How does Vivos Therapeutics compare to Check-Cap?

Vivos Therapeutics (NASDAQ:VVOS) and Check-Cap (NASDAQ:MBAI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

Vivos Therapeutics has a beta of 6.22, suggesting that its stock price is 522% more volatile than the broader market. Comparatively, Check-Cap has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 1.1% of Check-Cap shares are owned by institutional investors. 2.1% of Vivos Therapeutics shares are owned by company insiders. Comparatively, 0.5% of Check-Cap shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Check-Cap has a net margin of 0.00% compared to Vivos Therapeutics' net margin of -122.00%. Check-Cap's return on equity of 0.00% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-122.00%	-2,325.64%	-102.01%
Check-Cap	N/A	N/A	N/A

Vivos Therapeutics currently has a consensus price target of $2.80, suggesting a potential upside of 1,003.23%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Vivos Therapeutics is more favorable than Check-Cap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Check-Cap has lower revenue, but higher earnings than Vivos Therapeutics. Check-Cap is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$17.44M	0.20	-$21.17M	-$1.90	N/A
Check-Cap	N/A	N/A	$4.14M	-$14.07	N/A

In the previous week, Vivos Therapeutics had 2 more articles in the media than Check-Cap. MarketBeat recorded 5 mentions for Vivos Therapeutics and 3 mentions for Check-Cap. Vivos Therapeutics' average media sentiment score of 1.17 beat Check-Cap's score of 0.72 indicating that Vivos Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vivos Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Check-Cap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vivos Therapeutics beats Check-Cap on 11 of the 15 factors compared between the two stocks.

Get Vivos Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VVOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VVOS vs. The Competition

Export

Metric	Vivos Therapeutics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.68M	$5.94B	$7.40B	$12.81B
Dividend Yield	N/A	1.75%	2.53%	11.02%
P/E Ratio	-0.13	21.41	212.23	20.76
Price / Sales	0.20	69.39	630.33	94.71
Price / Cash	N/A	33.21	79.89	53.65
Price / Book	-0.69	6.24	13.14	6.20
Net Income	-$21.17M	$149.10M	$3.47B	$348.07M
7 Day Performance	-7.94%	0.53%	1.38%	0.67%
1 Month Performance	-35.44%	9.26%	8.62%	4.84%
1 Year Performance	-94.59%	6.82%	25.90%	16.83%

Vivos Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VVOS Vivos Therapeutics	2.7188 of 5 stars	$0.25 -4.3%	$2.80 +1,003.2%	-94.3%	$3.68M	$17.44M	N/A	160	News Coverage Positive News High Trading Volume
TMDIF Titan Medical	N/A	$0.12 -16.8%	N/A	-62.2%	$13.49M	$17.63M	N/A	50	Gap Down
IRIX IRIDEX	2.6113 of 5 stars	$0.74 +2.7%	$3.00 +308.2%	-43.6%	$12.76M	$52.67M	N/A	120	News Coverage Gap Up
ADGM Adagio Medical	2.341 of 5 stars	$0.54 -2.0%	$3.50 +549.4%	-56.7%	$12.30M	$600K	N/A	87	News Coverage Short Interest Increase
HSCS HeartSciences	2.6202 of 5 stars	$2.89 -3.6%	$8.00 +176.5%	-10.4%	$11.02M	N/A	N/A	10	Short Interest Decrease Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VVOS) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vivos Therapeutics (VVOS) Competitors

VVOS vs. TMDIF, IRIX, ADGM, HSCS, and MBAI

How does Vivos Therapeutics compare to Titan Medical?

Summary

How does Vivos Therapeutics compare to IRIDEX?

Summary

How does Vivos Therapeutics compare to Adagio Medical?

Summary

How does Vivos Therapeutics compare to HeartSciences?

Summary

How does Vivos Therapeutics compare to Check-Cap?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VVOS vs. The Competition

Vivos Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vivos Therapeutics (VVOS) Competitors

VVOS vs. TMDIF, IRIX, ADGM, HSCS, and MBAI

How does Vivos Therapeutics compare to Titan Medical?

Which has stronger earnings & valuation, TMDIF or VVOS?

Does the media favor TMDIF or VVOS?

Do insiders & institutionals hold more shares of TMDIF or VVOS?

Which has more risk and volatility, TMDIF or VVOS?

Do analysts rate TMDIF or VVOS?

Is TMDIF or VVOS more profitable?

Summary

How does Vivos Therapeutics compare to IRIDEX?

Is IRIX or VVOS more profitable?

Do institutionals and insiders hold more shares of IRIX or VVOS?

Which has more risk and volatility, IRIX or VVOS?

Does the media refer more to IRIX or VVOS?

Do analysts prefer IRIX or VVOS?

Which has higher valuation and earnings, IRIX or VVOS?

Summary

How does Vivos Therapeutics compare to Adagio Medical?

Is ADGM or VVOS more profitable?

Do analysts prefer ADGM or VVOS?

Do institutionals & insiders hold more shares of ADGM or VVOS?

Which has more volatility and risk, ADGM or VVOS?

Does the media refer more to ADGM or VVOS?

Which has stronger earnings & valuation, ADGM or VVOS?

Summary

How does Vivos Therapeutics compare to HeartSciences?

Does the media favor HSCS or VVOS?

Which has more volatility & risk, HSCS or VVOS?

Do analysts prefer HSCS or VVOS?

Is HSCS or VVOS more profitable?

Which has preferable valuation & earnings, HSCS or VVOS?

Do institutionals and insiders hold more shares of HSCS or VVOS?

Summary

How does Vivos Therapeutics compare to Check-Cap?

Which has more volatility & risk, VVOS or MBAI?

Do insiders & institutionals hold more shares of VVOS or MBAI?

Is VVOS or MBAI more profitable?

Do analysts recommend VVOS or MBAI?

Which has higher valuation & earnings, VVOS or MBAI?

Does the media refer more to VVOS or MBAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VVOS vs. The Competition

Vivos Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools